Request Demo

Last update 22 Oct 2026

Bexarotene

Last update 22 Oct 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid, 4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid, Bexarotene (JAN/USAN/INN)

+ [21]

Target

RXRs

Action

agonists, inhibitors

Mechanism

RXRs agonists(Retinoid X receptor agonists), Protein synthesis inhibitors

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [5]

Active Indication

Cutaneous T-Cell LymphomaCushing SyndromeEsophageal Squamous Cell Carcinoma+ [2]

Inactive Indication

Adult T-Cell Leukemia-LymphomaAdvanced breast cancerAdvanced Lung Non-Small Cell Carcinoma+ [10]

Originator Organization

Ligand Pharmaceuticals, Inc.

Active Organization

HAC Pharma SASU

Institute of Materia Medica

Minophagen Pharmaceutical Co. Ltd.

+ [4]

Inactive Organization

Ligand Pharmaceuticals, Inc.

Eisai, Inc.Bausch Health Ireland Ltd.

License Organization

Ewopharma AG

Ligand Pharmaceuticals, Inc.

Eisai Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

United States (29 Dec 1999),

Cutaneous T-Cell Lymphoma

RegulationOrphan Drug (United States), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC24H28O2

InChIKeyNAVMQTYZDKMPEU-UHFFFAOYSA-N

CAS Registry153559-49-0

Clinical Trials associated with Bexarotene

CTR20243921

/ RecruitingPhase 3

贝沙罗汀胶囊单药治疗既往接受至少一次全身治疗的复发或难治性皮肤T细胞淋巴瘤的开放、单臂、多中心临床试验

[Translation] An open, single-arm, multicenter clinical trial of bexarotene capsules as a monotherapy for relapsed or refractory cutaneous T-cell lymphoma who have received at least one previous systemic therapy

主要目的：在皮肤T细胞淋巴瘤(CTCL)中国人群中评价贝沙罗汀胶囊单药治疗既往接受至少一次全身治疗的复发或难治性皮肤T细胞淋巴瘤患者的有效性和安全性。次要目的：在CTCL中国人群中进行贝沙罗汀胶囊300mg/m2/d的药代动力学研究。

[Translation]

Primary objective: To evaluate the efficacy and safety of bexarotene capsules as a monotherapy in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who have received at least one previous systemic therapy in the Chinese population with cutaneous T-cell lymphoma (CTCL). Secondary objective: To conduct a pharmacokinetic study of bexarotene capsules 300 mg/m2/d in the Chinese population with CTCL.

Start Date18 Feb 2025

Sponsor / Collaborator

Bushu Pharmaceuticals Ltd.

[+3]

NCT05106192

/ WithdrawnNot ApplicableIIT

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

A study to compare pain differences between using MedJet needle-free drug-delivery system with standard of care treatment for cutaneous T-cell lymphomas and cutaneous B-cell lymphomas in participants.

Start Date01 Apr 2022

Sponsor / Collaborator

The Case Comprehensive Cancer Center

NCT05296304

/ RecruitingPhase 1IIT

A Phase Ib Trial Combining Bexarotene With Ultra-Low Dose Total Skin Electron Beam (Tseb) Radiotherapy For The Treatment Of Diffuse Cutaneous T-Cell Lymphomas

The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF).
Bexarotene is a form of vitamin A that activates proteins called retinoid X receptors, which may stop the growth of cancer cells and kill them. TSEB radiotherapy is a type of radiation therapy that treats the entire surface of the skin with very low doses of radiation to kill cancer cells and shrink tumors. This type of radiation does not pass through the outer layers of the skin into the tissues and organs below the skin.
The study researchers think that giving bexarotene treatment at the same time as treatment with TSEB radiotherapy may be more effective against MF than either treatment given alone or in sequence (one after the other).

Start Date16 Mar 2022

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

100 Clinical Results associated with Bexarotene

100 Translational Medicine associated with Bexarotene

100 Patents (Medical) associated with Bexarotene

1,106

Literatures (Medical) associated with Bexarotene

01 Oct 2026·Translational Oncology

A machine learning-derived and functionally validated circadian rhythm signature predicts clinical outcomes and in silico drug sensitivity in colorectal cancer

Article

Author: Xu, Qingqing ; Wei, Shanshan ; Jin, Huan

BACKGROUND:

Colorectal cancer (CRC) displays considerable heterogeneity in clinical outcomes, highlighting the need for reliable prognostic biomarkers. While the aberrant expression of circadian rhythm-related genes has been implicated in cancer pathogenesis, its comprehensive role in CRC progression and predicted therapeutic vulnerabilities remains inadequately characterized.

METHODS:

Bulk and single-cell RNA-sequencing data were integrated from multiple CRC cohorts. A circadian rhythm signature (CRS) was developed through machine learning algorithms and validated for prognostic value. Comprehensive analyses of tumor microenvironment, genomic alterations, and drug sensitivity were performed. Furthermore, the biological function of the core gene, BHLHE40, was validated in CRC cell lines through CCK-8, EdU, and wound healing assays.

RESULTS:

Single-cell analysis demonstrated an elevated expression signature of circadian rhythm-related genes in dendritic cells. The optimized CRS, comprising 14 circadian rhythm-related genes, successfully categorized patients into high- and low-risk groups. Patients with a high CRS showed markedly poorer overall survival and computationally inferred immunosuppressive features, including reduced CD8+ T cell infiltration and increased M2 macrophage polarization. Genomic analysis revealed enhanced mutation burden in TP53 and alterations in RTK-RAS/WNT pathways. Notably, in vitro assays confirmed that BHLHE40 is significantly overexpressed in CRC cells. Knockdown of BHLHE40 markedly inhibited tumor cell proliferation and migration. Drug sensitivity profiling identified bexarotene and SMER-3 as potential therapeutic options for high-CRS patients. A nomogram integrating CRS with clinical parameters demonstrated superior predictive accuracy for 1-, 3-, and 5-year survival.

CONCLUSIONS:

The CRS represents a promising prognostic biomarker that reflects tumor immune status and genomic features, providing valuable insights for personalized treatment strategies in CRC.

01 Oct 2026·JOURNAL OF DERMATOLOGY

Efficacy, Safety, and Maintenance Use of Topical Bexarotene in Early‐Stage Mycosis Fungoides: A Single‐Center Retrospective Real‐World Study

Article

Author: Demirsoy, Evren Odyakmaz ; Kıran, Rebiay ; Memet, Fatich ; Bayramgürler, Dilek ; Aktürk, Aysun Şikar ; Demirbaş, Abdullah ; Sayman, Nilgün

ABSTRACT:

Topical bexarotene 1% gel is an approved skin‐directed treatment for refractory or persistent stage IA‐IB cutaneous T‐cell lymphoma, but real‐world evidence in mycosis fungoides (MF), particularly regarding maintenance use after complete response, remains limited. We retrospectively reviewed 56 patients with histopathologically and immunohistochemically confirmed, previously treated stage IA‐IB MF who received topical bexarotene between 2009 and 2022. Clinical response, post‐treatment biopsy findings, adverse events, maintenance therapy, and relapse outcomes were analyzed. The cohort included 31 women and 25 men; 42 patients (75.0%) had stage IA and 14 (25.0%) had stage IB disease. Complete response (CR) was achieved in 20 patients (35.7%) and partial response in 15 (26.8%), yielding an overall response rate of 62.5%. Overall response was higher in stage IA than in stage IB disease (73.8% vs. 28.6%; p = 0.003) and in T1a than in T2a disease (77.1% vs. 36.4%; p = 0.044). All biopsied complete responders showed no MF‐compatible histology. Adverse events were exclusively local and manageable. Among 18 evaluable complete responders, relapse occurred in 15 (83.3%). Median time to relapse was longer with maintenance topical bexarotene than without maintenance (45 vs. 30 weeks; p = 0.039). Topical bexarotene appears effective and well tolerated in previously treated stage IA‐IB MF, with greatest benefit in limited patch‐stage disease. Maintenance use after CR may delay relapse, but this exploratory finding requires prospective validation.

01 Sep 2026·STROKE

Myeloid Cell–Specific Retinoid X Receptor Signaling Facilitates White Matter Repair and Stroke Recovery in Aged Mice

Article

Author: Leak, Rehana K ; Hassan, Sulaiman ; Shi, Yejie ; Hu, Xiaoming ; Lyu, Junxuan ; Li, Sicheng ; Zhang, Wenting ; Wu, Wan-Chen ; Chen, Jun ; Ye, Qing ; Chen, Huaijun ; Zhang, Feng ; Wu, Yun ; Pu, Hongjian ; Stetler, R Anne

BACKGROUND::

As stroke is the leading cause of long-term disability in the elderly, effective pharmacological therapies for neurorestoration remain an unmet clinical need. RXR (retinoid X receptor) signaling regulates inflammation and tissue repair, but the downstream repair processes linking RXR activation to stroke recovery in the aged central nervous system remain incompletely defined. We used aged mice to test the hypotheses that (1) pharmacological RXR stimulation with the brain-penetrant pan-RXR agonist bexarotene boosts poststroke recovery and (2) myeloid cell–specific RXR signaling facilitates white matter repair and underlies the therapeutic effects of bexarotene.

METHODS::

Permanent focal cerebral ischemia was induced in 18- to 22-month-old C57BL/6J male and female mice by distal middle cerebral artery occlusion. Pharmacological RXR activation and genetic ablation were achieved by poststroke bexarotene administration and generation of myeloid cell–specific RXR conditional knockout mice, respectively. Functional (sensorimotor and cognitive performance) and structural measures of central nervous system recovery were assessed up to 35 days after stroke.

RESULTS::

Poststroke treatment with bexarotene (5–10 mg/kg) improved sensorimotor performance in the rotarod, foot fault, and adhesive removal tests and alleviated cognitive deficits in the Morris water maze and passive avoidance tests. Bexarotene improved white matter integrity at 35 days after distal middle cerebral artery occlusion, without impacting white matter at 3 days or preventing gray matter atrophy at chronic injury stages. Bexarotene also suppressed immune cell infiltration and proinflammatory cytokine production, enhanced inflammation-resolving efferocytosis, promoted long-term oligodendrogenesis and angiogenesis, and fostered a prorepair central nervous system microenvironment. Accordingly, stroke outcomes were markedly worsened in aged RXR conditional knockout mice compared with age-matched wild-type mice, and the functional and white matter benefits of bexarotene were blocked in RXR conditional knockout mice.

CONCLUSIONS::

Myeloid RXR signaling promotes long-term stroke recovery in aged mice of both sexes and engages anti-inflammatory and prorepair mechanisms. Bexarotene warrants further evaluation as a potential neurorestorative therapy for stroke.

News (Medical) associated with Bexarotene

05 Aug 2026

·www.biospace.com

RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models

Investigators Present Data Supporting Disease-Modifying Potential of the Io Therapeutics RXR Agonist Compound IRX4204 in Parkinson’s Disease SPRING, Texas, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas, announced today the presentation of new research demonstrating that IRX4204, the company’s phase II clinical stage highly selective RXR nuclear receptor agonist, promotes degradation of alpha-synuclein protein in human neural cells. The findings were presented in an oral session titled “Targeting RXR Nuclear Receptor Signaling for Lysosomal Clearance of Alpha-Synuclein: Translational Perspectives and Emerging Pharmacological Applications in Parkinson’s Disease” at the International Retinoids Conference VIII in Niagara Falls, New York. The work was conducted by scientists at the Ann Romney Center for Neurologic Diseases at the Brigham and Women’s Hospital, Mass General Brigham. The presentation was delivered by Arati Tripathi, Ph.D., who led the research efforts with Ulf Dettmer, Ph.D. Parkinson’s disease (PD) is driven by abnormal aggregation, over-accumulation, and toxic effects of alpha-synuclein protein in dopaminergic neurons. Toxicity from accumulated alpha-synuclein leads to neuronal cell death and the progressive clinical manifestations of PD, including tremor, loss of motor and cognitive functions, and ultimately death. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Dr. Tripathi stated: “Alpha-synuclein is genetically tied to PD and accumulation of αSyn as intraneuronal aggregates in Lewy bodies and neurites is the neuropathological hallmark in PD patients. Strategies aimed at chronically reducing αSyn levels thus represent a rational approach to PD treatment and ultimately prevention. Our work demonstrated that pharmacological modulation of RXR targets alpha-synuclein clearance and counters proteotoxicity. In human cell models and human PD patient-derived induced pluripotent stem cell (iPSC) neurons, RXR agonism actively stimulates the autophagy-lysosome pathway to drive clearance of accumulated alpha-synuclein. This protective response was observed with multiple small-molecule RXR agonists, including bexarotene, an FDA-approved drug for T-cell lymphoma. For further validation, we utilized the experimental clinical-stage RXR agonist IRX4204. Our data show that IRX4204 markedly reduced alpha-synuclein levels in a human cellular model of PD, more potently than bexarotene. We look forward to building upon this promising preliminary observation.” Dr. Dettmer stated: “There are currently no approved drugs proven to slow or reverse progression of PD. Our studies on RXR-mediated alpha-synuclein degradation have important clinical implications. The data demonstrate a druggable pathway for inducing alpha-synuclein clearance from diseased neurons, and provide a mechanistic rationale for continued evaluation of selective RXR agonists such as IRX4204 for treatment of alpha-synuclein-associated pathologies, including Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy.” Martin E. Sanders, M.D., Chief Executive Officer of Io Therapeutics, stated: “IRX4204 is a phase II clinical-stage compound invented by Vidyasagar Vuligonda, Ph.D., Chief Science Officer of Io Therapeutics, and Roshantha Chandraratna, Ph.D., co-founder of the company. IRX4204 is approximately 100-fold more potent as an RXR agonist and far more selectively activates RXR than the earlier-generation RXR agonist bexarotene, which is associated with clinical adverse events linked to its off-target activation of multiple non-RXR nuclear receptors. The finding that IRX4204 promotes degradation of alpha-synuclein in human neural cells expands the drug’s previously reported mechanisms of action relevant to PD. In addition to the newly demonstrated effect of IRX4204 promoting alpha-synuclein clearance, we have previously reported that IRX4204 promotes recovery of functional motor disability, and increases dopaminergic neuron survival in a rat model of PD. IRX4204 has demonstrated an excellent chronic dosing safety pro clinical trials, including in patients with Parkinson’s disease and other conditions. The safety pro to date in more than 100 patients treated with IRX4204 shows it is likely to be suitably safe for chronic treatment of Parkinson’s disease. We previously reported that IRX4204 showed clinical anti-Parkinson’s disease activity assessed by the Unified Parkinson’s Disease Rating Scale (UPDRS) and the UPDRS Total Motor Subscale in an open-label, dose-ranging Phase I/II clinical trial of up to 28 days’ duration. Notably, 13 of 15 PD patients treated with IRX4204 showed UPDRS improvement, with some patients achieving more than 40% improvement from baseline in their UPDRS Total Motor Subscale scores within two to four weeks. Cumulatively, preclinical and clinical observations support the potential of IRX4204 to modify disease-course progression in PD. The company is planning future Phase IIb and Phase III clinical trials of IRX4204 in patients with Parkinson’s disease to study its effects on PD progression.” More information about Io Therapeutics, Inc. and its product development programs is available at . Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Io Therapeutics undertakes no obligation to update any forward-looking statements. Media Contact: Io Therapeutics, Inc. Spring, Texas info@io-therapeutics.com

Clinical ResultPhase 2Phase 1

02 Apr 2026

·allsci.com

Soligenix’s HyBryte shows improved response and tolerability vs Valchlor in small CTCL study

Soligenix (Nasdaq: SNGX) reported that a small comparative study of synthetic hypericin (HyBryte) versus mechlorethamine (Valchlor) in cutaneous T-cell lymphoma (CTCL) showed a higher treatment success rate and a cleaner tolerability profile for the photodynamic agent, though the sample size was too small to reach statistical significance. The HPN-CTCL-04 study is a randomized comparability study evaluating HyBryte against Valchlor over 12 weeks in patients with CTCL, measuring response across three to five prospectively identified index lesions per patient. At 12 weeks, 60% of patients in the HyBryte arm met the pre-specified treatment success threshold — defined as at least a 50% improvement in cumulative mCAILS score from baseline — compared with 20% in the Valchlor arm. Average cumulative mCAILS improvement was 52.5% versus 34.7%, respectively. The results did not achieve statistical significance, which the study’s principal investigator, Brian Poligone of the Rochester Skin Lymphoma Medical Group, attributed to the small sample size and a randomization that assigned patients with more extensive disease to the HyBryte arm. No HyBryte-treated patients experienced a treatment-related adverse event. In the Valchlor arm, 60% of patients had at least one related adverse event — including rashes, application site sensitivity, allergic contact dermatitis, and dermatitis — and one patient was permanently discontinued due to clinically significant allergic contact dermatitis. The tolerability contrast is the more interpretable signal from a study this size. The efficacy numbers, while directionally consistent with prior HyBryte data, carry limited inferential weight from what appears to be approximately five patients per arm. Cross-trial comparisons are limited by differences in patient populations, study designs, and endpoints, and the HPN-CTCL-04 data should be read as hypothesis-generating rather than confirmatory. HyBryte works by topical application of synthetic hypericin, a photosensitizer taken up by malignant T-cells in skin lesions and then activated approximately 24 hours later by visible light in the red-yellow spectrum. Because the mechanism does not involve DNA damage and uses visible rather than ultraviolet light, the therapy avoids the secondary malignancy risks associated with UV-based phototherapy, including melanoma, and may reduce the non-melanoma skin cancer risk associated with DNA-alkylating agents such as mechlorethamine. Valchlor, the most direct topical comparator, is a nitrogen mustard that covalently alkylates DNA and is approved only for patients who have already failed at least one prior skin-directed therapy. That positioning detail matters for understanding what Soligenix is trying to accomplish. No drug is specifically established as a front-line standard for early-stage CTCL. Every drug currently on the market — Valchlor, bexarotene, vorinostat, romidepsin, mogamulizumab, and the reformulated denileukin diftitox — generally sit later in the treatment sequence, with labels typically requiring prior skin-directed or systemic therapy depending on the agent. If Soligenix can complete a successful confirmatory Phase III trial, HyBryte would enter a regulatory space that no other approved agent currently occupies. The path to that approval runs through FLASH 2, a randomized, double-blind, placebo-controlled, multicenter study targeting approximately 80 patients with early-stage CTCL. The trial follows a 2023 setback in which the US FDA issued a refusal-to-file letter for HyBryte’s NDA, stating that the application was not sufficiently complete to permit substantive review. Subsequent discussions with the agency indicated that additional clinical data would be required, informing the design of the confirmatory study. In the first FLASH study, which enrolled 169 patients (166 evaluable) with Stage IA, IB, or IIA disease, 49% of patients who completed all three cycles demonstrated a treatment response (p<0.0001 versus placebo in Cycle 1). The confirmatory study has cleared its first safety review milestone, with a pre-specified blinded interim analysis expected in the second quarter of 2026. The regulatory picture remains split. FLASH 2 reflects alignment with the EMA, which has accepted a placebo-controlled design similar to the original FLASH study. By contrast, the US FDA has indicated a preference for a longer-duration active comparator trial, and discussions remain ongoing following the earlier refusal-to-file decision. The divergence introduces uncertainty around the US approval pathway specifically. For a disease affecting roughly 31,000 patients in the US and 38,000 in Europe, with no approved first-line option and treatment decisions heavily influenced by the safety risks of available therapies, the commercial and clinical logic behind a non-genotoxic, topical, visible-light-activated agent is coherent. Whether the Phase III data will support it remains to be seen. The blinded interim analysis from FLASH 2, expected mid-year, will be the next material data point for the program. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

31 Jul 2024

·www.fiercehealthcare.com

Wells Fargo relationship with Express Scripts under scrutiny in new lawsuit

Wells Fargo joins Johnson & Johnson as the most recent company sued over employee prescription drug price management. Wells Fargo is the most recent corporation to get sued, as alleged by former employees, for inadequately overseeing the price workers were forced to pay for prescription drug prices.In a class action lawsuit filed in federal court named Navarro et al v. Wells Fargo Company, employees say the company did not fulfill its fiduciary obligations. Under the Employee Retirement Income Security Act of 1974, employers are required to adequately manage employee benefits programs.The plaintiffs argue Wells Fargo’s management of the prescription drugs program resulted in higher premiums, out-of-pocket costs and limited wage growth because of the prices it agreed to pay Express Scripts, one of its pharmacy benefit managers, for generic drugs.Employees, they say in the suit, were forced to pay nearly $10,000 for a a prescription of fingolimod, used to treat multiple sclerosis, when the generic version could be purchased without insurance for less than a $1,000 at pharmacies like Cost Plus Drugs and Rite Aid. “No prudent fiduciary would agree to make its plan and participants/beneficiaries pay a price that is fifteen times higher than the price available to anyone who just walks into a pharmacy and pays without using their insurance,” the plaintiffs said in the lawsuit.Across approximately 300 generic drugs, Wells Fargo and Express Scripts made employees pay a markup on average of 114.97% what it costs pharmacies to obtain the drugs, the lawsuit alleges. For specialty drugs, employees said they paid a markup of 383% on average.Other prescriptions were far more expensive for employees at Express Scripts’ pharmacy Accredo. Bexarotene gel, available at Rite Aid for $3,750, cost employees nearly $70,000 from Accredo.“The price discrepancies noted herein are illustrative of a pervasive and systematic problem of unreasonable prescription drug charges, despite well-known alternatives available to defendants,” the lawsuit said. Plaintiffs in the lawsuit say Wells Fargo should have received better rates from Express Scripts or a different PBM, guided employees to more cost-effective options or utilized a pass-through PBM that doesn’t use spread pricing.Wells Fargo was also tagged with accusations that it should have operated with more expertise given its standing in the industry. Plaintiffs noted Wells Fargo publishes research on the economics of the pharma industry, hosts an annual healthcare conference with speakers from major PBMs, operates an employee benefits consulting practice and has publicly warned about rising prescription drug costs and business practices by Express Scripts.A similar lawsuit was filed against Johnson & Johnson in February by the same law firm, Fairmark Partners.“This case alleges that Wells Fargo has failed its employees once again, this time by agreeing to obviously unreasonable terms and prices with its PBM that cause workers to vastly overpay for prescription drugs,” said Michael Lieberman, an attorney with Fairmark Partners. “After years of scrutiny and with clear alternatives available, there are no excuses left for a large corporation like Wells Fargo to ignore its legal obligation to identify reasonable prescription drug coverage options for its employees.” Mark Cuban, founder of Cost Plus Drugs, said in a X post that this type of lawsuit can be expected to occur more often.“This lawsuit is going to happen over and over and over with self insured companies until they realize they have to drop their big 3 PBM and use a Pass Through PBM,” he said. “The good news is if they switch they will save money and get control of their claims data.”As well as the Wells Fargo health plan, top human resource employees were also named as defendants in the lawsuit.Wells Fargo and Express Scripts did not immediately respond to a request for comment from Fierce Healthcare.Aon, the broker for Wells Fargo, was also listed in the lawsuit. Express Scripts was not listed as a defendant.

Patent Infringement

100 Deals associated with Bexarotene

External Link

KEGG	Wiki	ATC	Drug Bank
D03106	Bexarotene	L01XF03	DB00307

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cutaneous T-Cell Lymphoma	United States	Bausch Health Ireland Ltd.	29 Dec 1999
Cutaneous T-Cell Lymphoma	United States	Dr. Jean Bausch GmbH & Co. KG	29 Dec 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alopecia Areata	Phase 3	United States	Ligand Pharmaceuticals, Inc.	01 May 2003
metastatic non-small cell lung cancer	Phase 3	United States	Eisai, Inc.	01 May 2002
metastatic non-small cell lung cancer	Phase 3	Austria	Eisai, Inc.	01 May 2002
metastatic non-small cell lung cancer	Phase 3	Canada	Eisai, Inc.	01 May 2002
metastatic non-small cell lung cancer	Phase 3	France	Eisai, Inc.	01 May 2002
metastatic non-small cell lung cancer	Phase 3	Germany	Eisai, Inc.	01 May 2002
metastatic non-small cell lung cancer	Phase 3	Spain	Eisai, Inc.	01 May 2002
Non-Small Cell Lung Cancer	Phase 3	United States	Eisai, Inc.	01 May 2002
Non-Small Cell Lung Cancer	Phase 3	Austria	Eisai, Inc.	01 May 2002
Non-Small Cell Lung Cancer	Phase 3	Canada	Eisai, Inc.	01 May 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAD2026	Not Applicable	Cutaneous T-Cell Lymphoma First line	12	Oral Bexarotene	njtpahifzg(lzsanxdnis) = All patients experienced some elevation of their triglycerides, and nearly half developed hypothyroid-like symptoms (e.g., constipation, cold intolerance). Both adverse events are consistent with established safety profiles within the literature and are commonly managed with standard triglyceride lowering therapies and thyroid hormone replacement therapies bzizxgmzlu (qgespdeala ) View more	Positive	27 Mar 2026
TCL-213 (SOHO2023)	Not Applicable	Peripheral T-Cell Lymphoma	-	Bexarotene 150 mg/m^2	gtkzrhuzhg(kmlsxnulns) = The most common toxicities were hypothyroidism and hyperlipidemia and effectively managed lhvnjmnppp (nxexogfvgq ) View more	Positive	01 Sep 2023
NCT03323658 (CTgov)	Phase 1	Breast Ductal Carcinoma \| Breast Carcinoma in Situ \| Atypical Lobular Breast Hyperplasia ... View more	24	Bexarotene (Dose Level 1)	ibppqcthch = uaguvmvkkh jmxufirfrx (uwhusaeszb, fstjytooxs - kvyixftafw) View more	-	06 Dec 2022
NCT03323658 (CTgov)	Phase 1		24	Bexarotene (Dose Level 2)	ibppqcthch = bvabqfifmr jmxufirfrx (uwhusaeszb, kcxldczzrq - fggxeimjwo) View more	-	06 Dec 2022
ISRCTN14265371 (CCMR One, ECTRIMS2021)	Phase 2	-	31	Bexarotene	rqmbkrnsxx(aiqmanizzz) = significant adverse events were observed on the trial krvtpuyhbt (dntymvswkd )	Positive	12 Oct 2021
ISRCTN14265371 (CCMR One, ECTRIMS2021)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	52	Bexarotene	aqwultjtlm(duxbillgre) = ovhhjnzegp ouevxautns (tfwmnnyovq ) View more	-	12 Oct 2021
ISRCTN14265371 (CCMR One, ECTRIMS2021)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	52	Placebo	aqwultjtlm(duxbillgre) = leqfpxceqc ouevxautns (tfwmnnyovq ) View more	-	12 Oct 2021
CCMR-One (ECTRIMS2020)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	52	Bexarotene 300mg/m2	eggtdzkzix(ukwenrxarf) = 100% of bexarotene patients experienced central hypothyroidism hjwtzoxrgr (kvyllfezga ) View more	Positive	07 Dec 2020
CCMR-One (ECTRIMS2020)	Phase 2	Multiple Sclerosis, Relapsing-Remitting	52	Placebo		Positive	07 Dec 2020
NCT00615784 (UPCC04407, CTgov)	Phase 2	Acute Myeloid Leukemia	24	Bexarotene	vegpxczjoq = tzefrfpncq ldsdyaatlm (ethzesbbdh, yphingyhbd - oyunynwrbp) View more	-	17 Nov 2020
NCT01007448 (CTgov)	Phase 4	Cutaneous T-Cell Lymphoma	59	Bexarotene	txyakvefxd = cimfxhwbzs pgeefljljr (gpzfgaaqxy, ppdnmfubdg - smcktwkwrr) View more	-	12 Nov 2019
NCT00153842 (CTgov)	Phase 1/2	Advanced Lung Non-Small Cell Carcinoma	33	Carboplatin+Bexarotene+Paclitaxel (Phase IB: Bexarotene 300mg, Paclitaxel and Carboplatin)	wsqaisntrq = oabgagvaky omjscmsexn (uzfuwmmzzn, mabvumejfo - rlntocvjuf)	-	06 Mar 2019
NCT00153842 (CTgov)	Phase 1/2	Advanced Lung Non-Small Cell Carcinoma	33	Carboplatin+Bexarotene+Paclitaxel (Phase IB: Bexarotene 400mg, Paclitaxel and Carboplatin)	wsqaisntrq = cgmfdrsdvf omjscmsexn (uzfuwmmzzn, jfobrjcwsd - swwudoavcb)	-	06 Mar 2019
NCT00125372 (CTgov)	Not Applicable	Resectable Lung Non-Small Cell Carcinoma	12	Tarceva+Targretin	mqcxynjlfp = dnsjzfjdqg teoxuyfqwm (wujqpoudtu, elhdvfpikc - ygeiqnsyfx) View more	-	13 Nov 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis